Alice Melao,  —

Regenxbio is exploring a new hereditary angioedema (HAE) treatment that harnesses viral vectors to deliver an antibody-based gene therapy, the company announced. The treatment will deliver the genetic sequence for an antibody that targets plasma kallikrein, a protein involved in swelling attacks in…

Attune Pharmaceuticals’ ATN-249, an investigational kallikrein inhibitor for the prevention of swelling attacks in hereditary angioedema (HAE) patients, was found generally safe and well-tolerated in a Phase 1 clinical trial with healthy volunteers, the company announced. Findings from this first-in-human trial (ACTRN12618000430235) were also presented during the recent Western Society…

KalVista Pharmaceuticals’ investigational candidate KVD900, being developed for the treatment of hereditary angioedema (HAE), is safe and effectively inhibits kallikrein, the main driver of HAE attacks, results from a Phase 1 clinical trial show. Following these positive results, the company is now launching a larger Phase 2…

Angioedema seems to predict poorer responses and lower chances of remission in chronic urticaria patients receiving Xolair (omalizumab), a retrospective study shows. The study, “Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study,” was published in the journal…

The U.S. Food and Drug Administration has rejected Pharming’s request to expand the label of Ruconest (conestat alfa) to include routine prevention of swelling attacks caused by hereditary angioedema (HAE). In a complete response letter indicating it had finished its review of the company’s supplemental biologics…

Medications that lower cholesterol levels, collectively known as statins, can in rare instances trigger angioedema episodes that are self-resolving if the patients stops using the statin, a case study reports. The study describes a side effect of Crestor (rosuvastatin), but its researchers caution that other, chemically-related statins could also…

The U.S. Food and Drug Administration (FDA) has granted fast track status to BCX7353, an investigational therapy being developed by BioCryst Pharmaceuticals, for the prevention of angioedema attacks in patients with hereditary angioedema. That status will support the development of BCX7353, speed its review and, depending on how it performs…

Activase (alteplase), a common treatment for stroke, may trigger angioedema of the mouth and tongue that can lead to a life-threatening situation if not treated promptly, a case report shows. The study, “Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator,” was published in the journal…

Entresto (sacubitril/valsartan) — an approved medication for heart failure — does not significantly increase the risk of angioedema compared with standard therapy Vasotec (enalapril), data from a Phase 3 trial show. The medication was also better at preventing deaths and heart failure-related hospitalizations than Vasotec, suggesting it could…

Treatment with human plasma-derived C1-INH is an effective and safe option for managing symptoms of severe hereditary angioedema during pregnancy and delivery, a Swedish case report suggests. The study, “Management of Women with Hereditary Angioedema During Pregnancy and Delivery,” was published in the Journal of Anesthesia, Surgery and…